In 2008 Novo Nordisk broke ground on one of the largest investments in the company's history: Establishing a new insulin filling plant near the city of Tianjin in China.

ALECTIA has delivered consultancy services regarding energy savings and ventilation design at Novo Nordisk’s new insulin plant. Energy-efficient design of the ventilation system and a number of energy-efficient strategies for regulating the amount of air in the system have provided Novo Nordisk with savings equalling tens of millions of Danish kroner in construction costs, and reduced the electricity consumption of the ventilation system by 50% compared with traditional design.

The company can further limit the costs for energy and reduce the release of CO2 and other pollutants from electricity and steam production, which are primarily based on coal in China.

The new insulin factory, which is Novo Nordisk’s primary production base in the Asia-Pacific region, will have considerably lower electricity consumption than the company’s other factories and is expected to be ready for commissioning in 2012.

ALECTIA has also been working with Novo Nordisk to create a comprehensive ‘Support Guide for Energy- Efficient HVAC Design’. The guide covers designing ventilation systems for all types of facilities, including facilities for production, research and administration.